new
world
alphavirus
belong
famili
togavirida
classifi
emerg
infecti
agent
categori
b
select
agent
studi
focus
role
host
extracellular
signalregul
kinas
erk
infecti
process
new
world
alphavirus
infect
human
cell
venezuelan
equin
enceph
viru
veev
result
activ
erksign
cascad
inhibit
small
molecul
inhibitor
result
inhibit
viral
multipl
inhibit
veev
due
potenti
effect
earli
late
stage
infecti
process
express
viral
protein
downregul
treat
cell
observ
influenc
nuclear
distribut
capsid
final
exert
broadspectrum
inhibitori
effect
new
world
alphaviru
multipl
thu
indic
host
kinas
erk
broadspectrum
candid
develop
novel
therapeut
new
world
alphavirus
new
world
alphavirus
venezuelan
equin
enceph
viru
veev
eastern
equin
enceph
viru
eeev
western
equin
enceph
viru
weev
infect
human
potenti
caus
encephalit
diseas
weaver
reisen
latin
america
record
multipl
confirm
case
new
world
alphaviru
infect
total
patient
hospit
enceph
among
patient
die
confirm
vee
carrera
et
al
owe
propens
caus
naturallyoccur
diseas
alphavirus
classifi
emerg
infecti
agent
new
world
alphavirus
potenti
extrem
infecti
aerosol
rout
therefor
explor
previous
potenti
bioweapon
zack
paessler
reason
veev
eeev
classifi
center
diseas
control
cdc
categori
b
select
agent
current
fdaapprov
therapeut
candid
vaccin
protect
human
new
world
alphaviru
infect
attenu
strain
veev
use
vaccin
select
atrisk
personnel
howev
concern
regard
safeti
consid
reactogen
vaccin
barrett
stanberri
around
vaccine
develop
diseas
symptom
typic
natur
vee
infect
volkova
et
al
therefor
ongo
effort
establish
effect
safer
vaccin
includ
vaccin
candid
deriv
attenu
strain
veev
martin
et
al
paessler
weaver
sharma
et
al
fdaapprov
antivir
therapi
rna
virus
ribavirin
ineffect
veev
weev
canonico
et
al
highlight
import
new
therapeut
approach
medic
countermeasur
new
world
alphavirus
virus
reli
host
cell
establish
product
infecti
cycl
virus
oblig
pathogen
known
modul
util
mani
host
event
includ
host
signaltransduct
mechan
deeper
understand
dynam
interact
host
pathogen
help
identif
novel
target
therapeut
exampl
mani
alphavirus
develop
abil
interfer
induct
host
cell
antivir
respons
burk
et
al
garmashova
et
al
anim
model
also
reveal
chang
gene
express
veevinfect
mous
brain
sharma
et
al
demonstr
host
kinas
content
list
avail
sciencedirect
journal
homepag
wwwelseviercomlocateyviro
glycogen
synthas
inhibitor
nuclear
factor
kappab
kinas
subunit
beta
modifi
upon
veev
infect
amaya
et
al
target
kinas
small
molecul
inhibitor
result
decreas
viral
replic
observ
underscor
potenti
hostbas
candid
therapeut
target
develop
antivir
new
world
alphavirus
advantag
confer
hostbas
therapeut
includ
decreas
potenti
develop
resist
strain
increas
probabl
broadspectrum
applic
treat
mani
viral
indic
concern
around
hostbas
therapeut
includ
low
threshold
toxic
henc
requir
stringent
analysi
inhibitor
induc
toxic
profil
host
host
mapk
extracellular
signalregul
kinas
erk
respond
stress
event
includ
infect
direct
multipl
downstream
event
like
inflamm
cell
death
hong
et
al
hu
et
al
xing
et
al
erk
exist
hereaft
refer
collect
central
posit
mapk
cascad
downstream
rasrafmekerk
signal
transduct
roskoski
roskoski
briefli
raf
kinas
act
phosphoryl
therefor
activ
collect
refer
dual
specif
phosphoryl
first
tyrosin
threonin
site
activ
segment
caus
subsequ
activ
roskoski
roskoski
activ
act
proteinserin
threonin
kinas
phosphoryl
cytosol
nuclear
substrat
yoon
seger
shaul
seger
form
activ
dimer
transloc
nucleu
phosphoryl
transcript
factor
regul
gene
transcript
chuderland
seger
parra
et
al
multipl
virus
known
activ
rasrafmekerk
signal
cascad
host
cell
mani
case
activ
correl
viral
replic
pleschka
specif
public
implic
erk
signal
pathway
regul
viral
replic
gene
express
coxsackieviru
luo
et
al
human
cytomegaloviru
boldogh
et
al
johnson
et
al
junin
viru
et
al
human
immunodefici
type
furler
uittenbogaart
et
al
coronaviru
cai
et
al
influenza
viru
particular
relev
studi
report
borna
diseas
viru
rna
viru
high
neurotrop
also
manipul
raf
mekerk
signal
cascad
vitro
appear
essenti
viral
spread
han
et
al
planz
et
al
demonstr
veev
infect
human
astrocytoma
cell
result
phosphoryl
multipl
target
protein
erk
signal
cascad
use
small
molecul
inhibitor
erk
demonstr
phosphoryl
play
import
role
veev
multipl
infect
cell
provid
data
suggest
earli
late
event
viral
infecti
cycl
suscept
inhibitor
extend
studi
virul
strain
veev
weev
eeev
demonstr
signal
broadspectrum
requir
new
world
alphavirus
establish
product
infecti
cycl
previou
studi
indic
host
kinas
includ
modul
veevinfect
cell
inhibit
kinas
small
molecul
inhibitor
result
decreas
viral
multipl
amaya
et
al
kehnhal
et
al
report
studi
multipl
compon
collect
constitut
nfkb
respons
phosphoryl
part
cascad
activ
process
amaya
et
al
base
previou
line
evid
hypothes
veev
infect
activ
host
phosphosign
cascad
infect
cell
inhibit
specif
event
cascad
effect
veev
multipl
util
revers
phase
protein
microarray
rppa
approach
identifi
chang
phosphosign
cascad
veevinfect
cell
success
use
approach
previou
studi
identifi
host
event
alter
virusinfect
cell
popova
et
al
popova
et
al
wulfkuhl
et
al
rppa
analysi
carri
describ
previous
popova
et
al
popova
et
al
briefli
cell
either
mock
infect
infect
attenu
strain
veev
infect
indic
throughout
manuscript
involv
exposur
cell
viru
one
hour
unless
otherwis
indic
refer
time
frame
infect
allow
happen
viral
overlay
remov
antibodi
use
analysi
includ
divers
rang
signal
cascad
growth
factor
signal
akt
signal
nfkb
signal
erk
signal
fold
differ
phosphoryl
candid
protein
seen
infect
cell
calcul
comparison
uninfect
cell
observ
multipl
signal
molecul
part
rasrafmekerk
signal
cascad
phosphoryl
veevinfect
cell
schemat
erk
signal
cascad
shown
fig
rppa
analysi
reveal
level
phosphoryl
higher
infect
cell
compar
uninfect
cell
fig
data
also
indic
phosphoryl
upstream
activ
also
increas
fig
furthermor
mani
downstream
target
includ
cruzalegui
et
al
carter
hunninghak
zhang
et
al
activ
infect
cell
fig
cumul
preliminari
rppa
data
indic
erk
signal
cascad
activ
veevinfect
cell
perform
independ
valid
experi
focu
phosphoryl
statu
infect
cell
carri
infect
cell
collect
total
protein
lysat
multipl
time
point
min
remov
initi
viral
inoculum
refer
henc
forth
infect
period
h
infect
period
lysat
subsequ
fraction
sdspage
analyz
western
blot
use
antibodi
phosphoryl
unphosphoryl
total
result
show
increas
phosphoryl
infect
cell
infect
period
fig
compar
lane
level
remain
consist
higher
infect
sampl
mock
sampl
entir
time
cours
distinguish
phosphoprofil
infect
cell
mockinfect
control
cell
fig
perform
addit
valid
experi
rppa
data
subject
protein
lysat
western
blot
use
antibodi
activ
profil
parallel
agre
data
obtain
rppa
process
fig
quantifi
level
infect
sampl
three
independ
experi
perform
fold
chang
mock
sampl
experi
averag
level
remain
around
minimum
increas
mock
throughout
time
cours
fig
analysi
total
level
indic
signific
differ
mock
infect
sampl
thu
indic
phosphoryl
event
independ
total
protein
level
cumul
data
includ
fig
suggest
infect
attenu
strain
veev
result
activ
erk
signal
cascad
phosphoryl
earli
time
point
infect
follow
valid
erk
phosphoryl
veevinfect
cell
want
determin
phosphoryl
event
essenti
viral
replic
defin
role
infect
inhibitor
phosphoryl
tyrphostin
employ
tyrphostin
cinnamonitril
report
cellperm
inhibitor
lipopolysaccharid
lp
induc
synthesi
tumor
necrosi
factoralpha
nitric
oxid
no
murin
periton
macrophag
novogrodski
et
al
also
block
lpsinduc
tyrosin
phosphoryl
erk
substrat
reduc
express
ino
lung
rat
treat
carrageenan
chatterje
et
al
evalu
antivir
efficaci
determin
toxic
profil
cell
seed
plate
h
later
increas
concentr
ad
well
triplic
dmso
ad
neg
solvent
control
cell
maintain
presenc
h
viabl
cell
quantifi
measur
luminesc
celltiterglo
assay
assay
result
show
inhibitor
nontox
cell
compar
dmso
treat
cell
concentr
rang
test
fig
subsequ
experi
use
concentr
mm
unless
otherwis
indic
next
step
want
test
whether
inhibit
phosphoryl
would
effect
replic
cell
plate
format
pretreat
h
media
inhibitor
remov
cell
infect
h
viral
overlay
remov
h
time
frame
media
ad
back
cell
cell
incub
h
supernat
collect
quantifi
infecti
viral
titer
use
plaqu
assay
control
includ
infect
cell
treat
dmso
concentr
treatment
increas
amount
viral
inhibit
increas
demonstr
dosedepend
respons
fig
determin
whether
inhibitori
effect
depend
multipl
infect
moi
cell
pretreat
h
dmso
alon
infect
three
differ
moi
cell
incub
h
describ
previous
supernat
collect
quantif
infecti
viral
titer
data
indic
even
higher
viral
titer
continu
inhibitori
viral
multipl
fig
assess
effect
express
viral
protein
whole
cell
lysat
obtain
h
postinfect
subject
western
blot
analysi
use
antibodi
veev
capsid
envelop
glycoprotein
h
postinfect
hpi
veev
capsid
protein
detect
treat
cell
howev
amount
capsid
protein
detect
time
point
untreat
cell
higher
untreat
cell
fig
compar
lane
differ
amount
capsid
protein
produc
treat
versu
untreat
cell
promin
h
time
point
compar
lane
unabl
detect
veev
glycoprotein
gp
hpi
could
detect
fairli
robust
express
glycoprotein
infect
untreat
cell
compar
treat
cell
time
point
fig
lane
quantifi
differ
treat
untreat
cell
time
point
two
independ
experi
found
treatment
modestli
reduc
capsid
express
greater
effect
gp
express
fig
indic
decreas
viral
structur
protein
level
treatment
may
partial
respons
decreas
viral
titer
also
conduct
western
blot
analysi
infect
treat
infect
cell
lysat
ensur
treatment
inde
inhibit
phosphoryl
use
antibodi
phosphoryl
unphosphoryl
total
abl
document
decreas
amount
phosphoryl
erk
time
point
test
presenc
fig
perform
similar
inhibit
efficaci
studi
vero
cell
determin
inhibit
observ
cell
cell
type
depend
phenomenon
end
first
evalu
cytotox
vero
cell
determin
mm
concentr
evok
cytotox
respons
fig
determin
could
inhibit
multipl
vero
cell
pretreat
cell
h
infect
infecti
titer
measur
plaqu
assay
h
post
infect
period
result
shown
fig
indic
could
inhibit
even
permiss
cell
line
vero
cell
albeit
extent
inhibit
lesser
observ
cell
cumul
data
suggest
nontox
concentr
inhibit
phosphoryl
decreas
viral
protein
express
neg
influenc
multipl
infect
cell
inhibit
phosphoryl
inhibit
nuclear
accumul
erk
interfer
nuclear
accumul
veev
capsid
protein
phosphoryl
nuclear
cytosol
target
typic
known
dimer
transloc
nucleu
act
multipl
transcript
factor
roskoski
inhibit
phosphoryl
small
molecul
inhibitor
affect
nuclear
transloc
roskoski
therefor
confirm
treatment
inde
result
decreas
phosphoryl
cell
investig
intracellular
local
veev
infect
presenc
absenc
differ
time
point
use
confoc
microscopi
describ
previous
amaya
et
al
briefli
cell
seed
chamber
slide
infect
viru
h
infect
period
cell
fix
probe
antibodi
veev
capsid
h
nuclear
enrich
observ
cell
infect
fig
defin
nuclear
enrich
visual
assess
local
nucleu
contrast
mock
cell
show
enrich
wherea
treat
cell
enrich
therefor
treatment
result
decreas
nuclear
thu
attest
inhibit
erk
phosphoryl
observ
ad
support
data
present
fig
h
infect
cell
demonstr
nuclear
enrich
mockinfect
cell
show
nuclear
fig
capsid
stain
detect
cell
expos
viru
treat
comparison
capsid
stain
reduc
infect
treat
cell
overal
capsid
stain
reduc
treat
cell
observ
differ
distribut
capsid
nucleu
cytoplasm
infect
cell
regardless
treatment
thu
indic
signal
event
play
role
nuclearcytoplasm
transport
veev
capsid
protein
infect
cell
cumul
microscopi
studi
attest
inhibitori
action
neg
influenc
nuclear
accumul
support
potenti
erkmedi
phosphoryl
control
nuclearcytoplasm
transport
veev
capsid
protein
studi
thu
far
analyz
inhibit
multipl
static
phenomenon
h
infect
period
would
inform
determin
overal
replic
kinet
viru
impact
treatment
end
cell
pretreat
h
dmso
alon
control
cell
infect
supernat
collect
multipl
time
point
h
postinfect
plaqu
assay
perform
result
shown
fig
demonstr
overal
decreas
viral
replic
kinet
could
clearli
observ
earli
h
post
infect
period
exacerb
subsequ
time
point
perform
timeofaddit
experi
attempt
identifi
specif
time
frame
infecti
cycl
inhibit
could
detect
cell
treat
either
dmso
alon
indic
time
fig
supernat
collect
h
quantifi
infecti
viral
titer
observ
cell
pretreat
two
hour
infect
h
pre
robust
inhibit
appar
continu
inhibitori
ad
hpi
h
post
extent
inhibit
robust
pretreat
drug
ad
hpi
inhibitori
potenti
decreas
fig
also
observ
modest
statist
signific
reduct
titer
drug
ad
h
post
infect
period
could
potenti
implic
late
event
well
howev
unclear
whether
appar
inhibit
seen
h
time
point
due
late
event
first
round
viral
multipl
earli
event
second
round
multipl
cumul
experiment
addit
fig
treatment
decreas
nuclear
pool
without
influenc
capsid
local
nucleu
cell
seed
slide
infect
everi
variabl
least
two
independ
well
analyz
cell
fix
b
hpi
stain
antibodi
veev
capsid
red
green
slide
also
stain
dapi
stain
nucleu
blue
imag
collect
use
nikon
eclips
acquir
object
imag
repres
multipl
field
imag
variabl
three
independ
experi
conduct
multipl
time
point
infect
period
reveal
may
affect
viral
multipl
earli
late
time
frame
infecti
process
fact
pretreat
strategi
efficaci
hand
could
also
impli
longer
drug
avail
system
greater
extent
inhibit
observ
time
want
determin
directli
virucid
natur
may
also
contribut
observ
inhibit
concentr
toward
earli
time
point
address
possibl
perform
modifi
plaqu
reduct
neutral
assay
incub
directli
h
room
temperatur
incub
infect
viru
quantifi
plaqu
assay
data
indic
ad
cell
presenc
viru
inhibitori
action
expect
act
posit
control
inhibitori
potenti
fig
howev
incub
viru
directli
part
experi
absenc
cell
quantifi
infect
viru
plaqu
assay
differ
viru
expos
drug
viru
expos
drug
thu
indic
exert
direct
virucid
activ
gain
insight
antivir
effect
multipl
perform
slight
variat
time
addit
studi
drug
made
avail
limit
block
time
experiment
organ
involv
ad
drug
differ
time
point
follow
remov
drug
replac
fresh
media
fig
cell
treat
indic
time
supernat
collect
h
quantifi
infecti
viral
titer
fig
observ
cell
pre
treat
h
pre
robust
inhibit
fig
howev
inhibit
even
robust
drug
ad
directli
one
hour
infect
period
one
hour
hpi
later
time
point
modestli
efficaci
parallel
earlier
observ
addit
drug
h
window
result
statist
signific
decreas
viral
multipl
may
due
influenc
late
stage
viral
multipl
reflect
earli
event
second
round
viral
multipl
attempt
determin
whether
inhibit
viral
multipl
may
also
result
aberr
transport
local
structur
protein
glycoprotein
endoplasm
reticulum
er
golgi
apparatu
snyder
mukhopadhyay
end
perform
confoc
microscopi
experi
use
antibodi
er
golgi
apparatu
context
infect
without
assess
glycoprotein
distribut
er
golgi
carri
experi
use
veev
glycoprotein
antiserum
analyz
distribut
glycoprotein
er
golgi
h
post
infect
period
hand
abl
detect
glycoprotein
er
h
time
point
er
signal
steadili
decreas
time
cours
analysi
fig
b
abl
observ
distinct
coloc
glycoprotein
golgi
apparatu
within
time
frame
includ
studi
fig
presenc
notic
glycoprotein
signal
er
reduc
h
time
point
differ
er
signal
treat
untreat
cell
increas
h
time
point
suggest
may
effect
er
local
veev
glycoprotein
hypothes
inhibit
activ
result
downregul
veev
multipl
activ
prime
could
contribut
upregul
veev
multipl
employ
mapk
activ
erk
ceramid
fig
inhibit
phosphoryl
result
less
veev
glycoprotein
endoplasm
reticulum
cell
seed
slide
infect
everi
variabl
least
three
independ
well
analyz
cell
fix
hpi
stain
antibodi
veev
glycoprotein
red
endoplasm
reticulum
er
marker
green
slide
also
stain
dapi
stain
nucleu
blue
slide
also
fix
stain
golgi
marker
green
time
point
imag
collect
use
nikon
eclips
acquir
object
imag
repres
multipl
field
imag
variabl
two
independ
experi
conduct
b
cell
triplic
well
two
experi
count
random
coloc
veev
glycoprotein
er
presenc
absenc
rain
et
al
prime
cell
activ
phosphoryl
prior
infect
first
step
assess
toxic
compound
cell
found
loss
viabil
concentr
compound
fig
treatment
greater
equal
howev
notic
level
toxic
therefor
decid
proceed
treatment
analysi
viral
replic
kinet
erk
activ
prior
infect
valid
ceramid
treatment
activ
experiment
condit
collect
whole
cell
protein
lysat
multipl
time
point
presenc
absenc
ceramid
perform
western
blot
analysi
data
indic
ceramid
treatment
increas
amount
phosphoryl
treatment
addit
ceramid
result
earlier
activ
erk
signal
fig
compar
lane
treatment
confirm
ceramid
inde
activ
signal
cell
type
determin
ceramid
activ
erk
prior
infect
contribut
increas
viral
multipl
cell
treat
h
either
dmso
alon
ceramid
infect
h
supernat
collect
hpi
quantifi
plaqu
assay
data
indic
viru
titer
statist
significantli
higher
ceramid
treatment
h
analysi
point
fig
h
ceramid
sampl
increas
dmso
sampl
assess
effect
ceramid
treatment
express
viral
protein
saw
modest
increas
veev
capsid
glycoprotein
gp
cell
treat
ceramid
infect
fig
two
independ
experi
conduct
protein
level
normal
quantifi
experi
averag
shown
bar
fig
next
want
determin
activ
effect
amount
viral
rna
produc
treat
cell
assess
level
intracellular
viral
rna
perform
quantit
rtpcr
qrtpcr
veev
specif
primer
hpi
saw
greatest
differ
infecti
viral
titer
isol
intracellular
rna
subject
qrtpcr
analysi
genom
copi
show
notic
differ
viral
rna
accumul
cell
depend
ceramid
treatment
fig
supernat
correspond
h
time
point
analyz
pcr
method
subject
plaqu
assay
quantifi
infecti
viru
supernat
sampl
interestingli
plaqu
assay
reveal
increas
infecti
viral
titer
presenc
ceramid
although
viral
rna
level
similar
dmso
control
fig
assess
whether
treatment
result
reduct
cytopath
effect
cpe
context
infect
earlier
experi
use
hostbas
inhibitor
multipl
allud
possibl
increas
surviv
infect
cell
kinet
viral
multipl
decreas
e
qrtpcr
result
veev
genom
copi
hpi
right
supernat
exact
well
examin
qrtpcr
intracellular
genom
copi
subject
plaqu
assay
quantifi
infecti
viru
amaya
et
al
test
whether
treatment
reduc
cpe
infect
cell
imag
infect
untreat
cell
infect
cell
hpi
fig
infect
cell
panel
h
l
appear
healthier
infect
untreat
cell
panel
c
g
k
phenotyp
resembl
mock
infect
untreat
cell
e
treatment
chang
morpholog
cell
b
f
j
compar
mock
infect
untreat
cell
next
adopt
quantit
cell
surviv
assay
verifi
increas
cell
viabil
treat
surviv
assay
measur
fraction
live
cell
celltiterglo
hpi
presenc
absenc
fig
c
hpi
infect
cell
treat
dmso
alon
drop
luminesc
seen
uninfect
cell
howev
cell
show
luminesc
compar
dmso
alon
hpi
treat
cell
surviv
dmso
alon
control
collect
data
support
idea
conjunct
exert
antivir
activ
inhibit
erk
phosphoryl
earli
stage
infect
inhibitor
contribut
increas
surviv
infect
cell
extend
analysi
depend
inhibit
phosphoryl
virul
strain
new
world
alphavirus
experi
util
trinidad
donkey
trd
strain
veev
strain
eeev
california
strain
weev
end
cell
pretreat
dmso
infect
virul
strain
infect
perform
condit
media
replac
supernat
collect
h
later
plaqu
assay
perform
quantifi
infecti
viral
particl
fig
addit
treatment
reduc
viral
titer
veev
trd
pfuml
pfuml
decreas
case
eeev
treatment
result
overal
drop
pfuml
pfuml
weev
treatment
contribut
decreas
viral
titer
pfuml
pfuml
result
support
hypothesi
like
broadspectrum
target
develop
antivir
new
world
alphavirus
final
want
know
inhibitor
rasrafmekerk
signal
cascad
would
similarli
affect
veev
multipl
end
employ
variou
inhibitor
character
effect
multipl
cell
chose
evalu
among
alreadi
fda
approv
cancer
therapi
would
therefor
strong
candid
repurpos
antivir
therapeut
alphavirus
toxic
profil
compound
evalu
concentr
cell
celltiterglo
assay
describ
previous
show
signific
decreas
cell
viabil
treatment
rel
nontox
fig
compound
nontox
concentr
cell
pre
treat
mek
inhibitor
except
test
infect
viru
supernat
collect
h
later
subject
plaqu
assay
result
show
abl
decreas
veev
multipl
log
also
effect
lesser
extent
effect
inhibit
multipl
system
fig
cumul
data
indic
inhibit
signal
attract
option
inhibit
alphaviru
multipl
human
cell
innat
immun
respons
establish
earli
follow
exposur
infecti
agent
play
essenti
role
pathogen
control
protect
host
innat
immun
mechan
shape
host
phosphosign
respons
undergo
fairli
elabor
modul
upon
cellular
insult
includ
exposur
infecti
agent
viru
infect
well
document
activ
mani
host
signal
respons
often
shift
balanc
host
surviv
cell
death
mani
virus
known
hijack
intrins
host
respons
enabl
establish
product
viral
infect
often
hijack
mechan
involv
addit
host
respons
also
modifi
cumul
result
suppress
host
environ
viru
multipli
without
interfer
innat
host
protect
mechan
interferon
respons
fact
new
world
alphavirus
includ
veev
weev
known
suppress
host
interferon
respons
mechan
involv
viral
capsid
protein
atasheva
et
al
peltier
et
al
part
pathogenesi
new
world
alphavirus
also
known
trigger
apoptosi
infect
cell
mediat
host
signal
pathway
griffin
hardwick
previou
studi
use
inhibitor
establish
inhibit
host
phosphosign
event
exert
inhibitori
effect
viral
multipl
infect
human
cell
amaya
et
al
kehnhal
et
al
narayanan
et
al
current
studi
provid
evid
activ
phosphoryl
earli
time
point
follow
exposur
strain
veev
fig
observ
phosphoryl
increas
infect
cell
signific
chang
observ
level
total
protein
indic
increas
phosphoryl
form
independ
de
novo
protein
synthesi
fig
small
molecul
inhibitor
phosphoryl
use
nontox
rang
potenti
inhibit
viral
multipl
fig
observ
inhibit
mediat
interrupt
potenti
earli
late
event
infecti
process
data
suggest
compound
directli
virucid
hypothes
like
interfer
host
process
essenti
intern
viru
go
subsequ
step
capsid
shed
releas
viral
nucleic
acid
cytoplasm
cell
addit
step
inhibitori
process
may
involv
abber
packag
viral
egress
ongo
research
address
possibl
includ
analysi
host
event
essenti
intracellular
transport
viru
may
involv
cytoskelet
dynam
hypothesi
negat
possibl
direct
erkmedi
modif
viral
protein
exampl
viral
nonstructur
protein
nsp
may
phosphoryl
host
kinas
influenc
function
one
alphaviru
protein
known
heavili
phosphoryl
nonstructur
protein
li
et
al
et
al
vihinen
saarinen
critic
regul
neg
strand
synthesi
affect
virul
howev
exact
role
viral
infecti
cycl
continu
remain
unknown
earlier
studi
indic
may
phosphoryl
character
phosphoryl
statu
presenc
inhibitor
contain
potenti
phosphoryl
site
interest
aspect
current
investig
laboratori
addit
appear
local
glycoprotein
er
infect
cell
may
affect
fig
therefor
interest
specul
may
effect
viral
particl
assembl
packag
studi
suggest
inhibit
erk
phosphoryl
may
also
contribut
increas
surviv
infect
cell
decreas
cpe
follow
alphaviru
infect
fig
virus
varicellazost
viru
vzv
document
control
apoptosi
infect
cell
modul
multipl
aspect
apoptot
signal
respons
often
culmin
differenti
phosphoryl
key
effector
molecul
like
bad
bax
bim
etc
liu
cohen
interestingli
demonstr
vzv
protein
trigger
phosphoryl
erk
order
inhibit
apoptosi
liu
et
al
would
inform
quantifi
statu
variou
apoptot
event
veevinfect
cell
presenc
absenc
effect
inhibitor
like
determin
mechan
mediat
cell
death
infect
cell
observ
mek
erk
phosphoryl
veevinfect
cell
erk
inhibitor
effect
interfer
viral
multipl
open
door
fdaapprov
mek
erk
inhibitor
includ
trametinib
selumetinib
cobemetinib
repurpos
antivir
novel
indic
new
world
alphaviru
therapeut
repurpos
mek
erk
inhibitor
addit
attract
evid
inhibit
erk
broadspectrum
effect
multipl
three
new
world
alphavirus
fig
hand
least
one
fda
approv
inhibitor
mekerk
cascad
efficaci
inhibit
veev
multipl
even
though
better
inhibitori
potenti
fig
rppa
analysi
identifi
mani
signal
node
rasrafmekerk
signal
cascad
phosphoryl
infect
cell
focus
current
studi
erk
phosphoryl
statu
studi
open
new
avenu
explor
consequ
phosphoryl
addit
target
cascad
alphaviru
replic
exampl
phosphoryl
demonstr
intim
associ
replic
sarscoronaviru
mizutani
et
al
would
interest
determin
whether
inhibitor
multipl
erk
phosphosign
node
exert
synergist
potent
inhibit
viru
use
combinatori
capac
human
astrocytoma
cell
cell
african
green
monkey
kidney
epitheli
cell
vero
cell
maintain
dmem
supplement
fetal
bovin
serum
fb
penicillinstreptomycin
lglutamin
co
cell
seed
plate
order
attain
confluenc
within
h
media
remov
prior
infect
save
refer
condit
media
cell
infect
h
allow
viral
adsorpt
viral
inoculum
remov
cell
wash
pb
condit
media
replac
cell
incub
co
overnight
supernat
collect
hpi
store
analyz
small
molecul
includ
ceramid
santa
cruz
biotechnolog
catalogu
cell
signal
technolog
catalogu
selleckchem
catalogu
selleckchem
catalogu
selleckchem
catalogu
compound
dissolv
dimethyl
sulfoxid
dmso
cell
seed
plate
densiti
cell
per
well
next
day
cell
pretreat
compound
h
drug
concentr
maintain
manner
exceed
dmso
final
concentr
per
well
condit
media
contain
compound
remov
viral
infect
proceed
multipl
infect
moi
h
viral
inocula
remov
replac
condit
media
compound
cell
incub
h
co
supernat
collect
store
analyz
cell
viabil
measur
use
celltiterglo
luminesc
cell
viabil
kit
promega
catalog
accord
manufactur
instruct
briefli
cell
seed
white
wall
plate
cell
per
well
incub
h
co
cell
treat
dmso
control
incub
h
co
determin
cell
viabil
celltiterglo
reagent
ad
cell
ratio
plate
shaken
min
room
temperatur
incub
min
room
temperatur
luminesc
detect
use
dtx
multimod
detector
beckman
coulter
method
rppa
describ
previous
popova
et
al
popova
et
al
cell
plate
format
infect
one
hour
co
h
cell
wash
pb
lyse
boil
min
lysi
buffer
composit
follow
mixtur
tper
reagent
pierc
il
trisglycin
sd
sampl
buffer
novex
invitrogen
ca
presenc
mercaptoethanol
proteas
phosphatas
inhibitor
halt
cocktail
pierc
lyse
sampl
store
readi
rppa
studi
conduct
rppa
studi
approxim
nl
sampl
print
onto
nitrocellulos
slide
whatman
use
highresolut
array
aushon
biosystem
billerica
randomli
chose
slide
stain
cyprorubi
stain
quantifi
total
protein
use
signal
normal
describ
print
slide
stain
use
dako
autostain
specif
antibodi
use
biotinlink
peroxidasecatalyz
signal
amplif
dako
csa
kit
slide
stain
secondari
biotinyl
goat
antirabbit
igg
antibodi
vector
lab
burlingam
ca
imag
umax
powerlook
iii
scanner
umax
dalla
tx
imag
analyz
softwar
alphaas
fc
alpha
innotech
everi
antibodi
use
averag
pixel
intens
valu
neg
control
stain
second
antibodi
subtract
averag
pixel
intens
valu
normal
correspond
averag
valu
total
protein
intens
signal
intens
everi
antibodi
spot
statist
evalu
use
graphpad
prism
softwar
graphpad
softwar
ca
antibodi
use
rppa
array
follow
phosphoryl
protein
purchas
cell
signal
catalog
number
antibodi
indic
parenthesi
braf
craf
erk
cell
seed
densiti
cell
per
well
plate
cell
mocktreat
treat
treat
h
infect
h
condit
perform
triplic
well
random
section
well
imag
hpi
hpi
use
zeiss
microscop
pixera
viewfind
softwar
vero
cell
seed
densiti
cell
per
well
plate
viral
supernat
dilut
dmem
use
infect
vero
cell
technic
duplic
plate
incub
co
h
occasion
rock
ml
overlay
compris
agaros
ad
well
solidifi
plate
incub
addit
h
co
complet
assay
addit
formaldehyd
solut
ad
surfac
agaros
plug
follow
h
incub
room
temperatur
plate
rins
dih
agaros
plug
remov
crystal
violet
solut
contain
ethanol
ad
well
incub
room
temperatur
rock
min
plate
rins
dih
visibl
plaqu
count
determin
viral
titer
plaqu
form
unit
per
ml
pfuml
viral
stock
pfuml
incub
room
temperatur
h
either
presenc
absenc
gentl
mix
sampl
directli
subject
plaqu
assay
order
obtain
whole
cell
lysat
media
remov
cell
cell
wash
pb
next
cell
lyse
lysi
buffer
consist
mixtur
tper
reagent
pierc
catalogu
trisglycin
sd
sampl
buffer
invitrogen
catalogu
proteas
phosphatas
inhibitor
cocktail
halt
mixtur
pierc
cell
lysi
buffer
incub
room
temperatur
one
minut
collect
cell
lysat
boil
min
store
analyz
cell
pretreat
ceramid
h
infect
moi
control
cell
treat
dmso
h
post
infect
cell
lyse
use
total
rna
isol
kit
life
technolog
per
manufactur
instruct
intracellular
viral
rna
quantit
use
qrtpcr
primer
probe
nucleotid
veev
kehnhal
et
al
qrtpcr
cycl
condit
follow
cycl
min
cycl
min
cycl
min
use
stepon
plu
real
time
pcr
system
primer
probe
pair
use
origin
describ
juland
forward
primer
tctgacaagacgttcccaatca
revers
primer
gaataactt
ccctccgaccaca
taqman
probe
n
n
n
juland
et
al
qrtpcr
assay
perform
use
biorad
itaq
univers
probe
onestep
mix
biorad
absolut
quantif
calcul
base
threshold
cycl
ct
rel
standard
curv
whole
cell
lysat
separ
trisglycin
gel
v
transfer
polyvinyl
difluorid
pvdf
membran
use
iblot
gel
transfer
system
invitrogen
membran
block
dri
milk
pbstween
bsa
pbstween
room
temperatur
primari
antibodi
veev
capsid
bei
resourc
nr
veev
glycoprotein
bei
resourc
nr
perk
thr
cell
signal
technolog
catalogu
erk
antibodi
cell
signal
technolog
catalogu
cell
signal
technolog
catalogu
hrpconjug
actin
abcam
catalogu
use
accord
manufactur
instruct
blot
incub
primari
antibodi
overnight
follow
wash
pbstween
blot
incub
respect
secondari
hrpcoupl
antibodi
h
wash
pbstween
wash
pb
membran
visual
chemiluminesc
use
supersign
west
femto
maximum
sensit
substrat
kit
thermoscientif
biorad
molecular
imag
chemidoc
xr
system
biorad
immunofluoresc
cell
seed
densiti
cellswel
chamber
slide
cell
either
mocktreat
treat
infect
moi
cell
fix
paraformaldehyd
min
permeabil
triton
pb
min
slide
wash
pb
block
room
temperatur
min
bsa
slide
incub
primari
antibodi
h
dark
wash
three
time
pb
incub
respect
secondari
antibodi
alexa
fluor
antibodi
invitrogen
h
dark
primari
antibodi
marker
endoplasm
reticulum
golgi
includ
pdi
respect
cell
signal
technolog
catalogu
slide
wash
three
time
pb
incub
dapi
min
dark
room
temperatur
follow
addit
pb
wash
slide
mount
fluoromount
g
southernbiotech
catalogu
store
dark
overnight
cell
imag
use
nikon
eclips
imag
taken
object
graph
data
analys
perform
use
r
statist
languag
perform
three
independ
experi
use
separ
harvest
viral
supernat
time
experi
includ
three
biolog
sampl
per
group
record
raw
plaqu
count
plaqu
assay
determin
pfuml
figur
present
scatter
plot
overlaid
box
whisker
plot
box
whisker
plot
convent
mean
use
graphic
represent
well
perform
wilcoxon
rank
sum
test
assess
differ
among
treatment
group
pvalu
less
consid
statist
signific
signific
result
indic
figur
follow
fashion
pvalu
nnn
pvalu
nn
pvalu
n
